What question did this study set out to answer?

To evaluate the binding affinity, selectivity, and in vivo imaging characteristics of [18F]T807 as a novel tau radiotracer for Alzheimer's disease.

February 11, 2013Alzheimer s & Dementia

[¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

View Full Paper

Ask AI

Bookmark

To evaluate the binding affinity, selectivity, and in vivo imaging characteristics of [18F]T807 as a novel tau radiotracer for Alzheimer's disease.
Synthesized and characterized the novel radiotracer [18F]T807 for tau positron emission tomography imaging.
Assessed in vitro binding affinity and selectivity toward paired helical filament tau (PHF-tau) and evaluated in vivo properties.
[18F]T807 demonstrated high binding affinity and marked selectivity for PHF-tau.
The compound exhibited favorable in vivo pharmacokinetic and imaging properties, identifying it as a promising diagnostic candidate for Alzheimer's disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical evaluation reveals high selectivity of [18F]T807 for paired helical filament tau, suggesting its viability as a positron emission tomography tracer for Alzheimer's disease.

Cite This Study

Xia et al. (2013) studied this question.

synapsesocial.com/papers/69de5e697ed287395e558a50 https://doi.org/10.1016/j.jalz.2012.11.008

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation reveals high selectivity of [18F]T807 for paired helical filament tau, suggesting its viability as a positron emission tomography tracer for Alzheimer's disease.

[¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Key Points

Discussion

Implication

Cite This Study

[¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider